H.R. 10887 · 119th Congress (2025–2027)
Protecting Consumer Access to Generic Drugs Act of 2026
To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
CRS summary not yet available.
Referred to committee
Latest actionReferred to committee
This bill’s path
This is H.R. 10887’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. Seth Magaziner (D-RI-2)
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
Referred to committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sources
- Congress.gov action
- House floor actions
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Protecting Consumer Access to Generic Drugs Act of 2026
Short title, Display title · Introduced in House
To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.
Official title · Introduced in House